A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2017
At a glance
- Drugs Amcasertib (Primary) ; Napabucasin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boston Biomedical
- 19 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Oct 2017.
- 12 Sep 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2017.
- 04 Apr 2016 Planned number of patients changed from 40 to 120 as reported by Clinicaltrials.gov record.